246 related articles for article (PubMed ID: 12515389)
1. Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.
't Hoen PA; Out R; Commandeur JN; Vermeulen NP; van Batenburg FH; Manoharan M; van Berkel TJ; Biessen EA; Bijsterbosch MK
RNA; 2002 Dec; 8(12):1572-83. PubMed ID: 12515389
[TBL] [Abstract][Full Text] [Related]
2. Selection of effective antisense oligodeoxynucleotides with a green fluorescent protein-based assay. Discovery of selective and potent inhibitors of glutathione S-transferase Mu expression.
't Hoen PA; Rosema BS; Commandeur JN; Vermeulen NP; Manoharan M; van Berkel TJ; Biessen EA; Bijsterbosch MK
Eur J Biochem; 2002 May; 269(10):2574-83. PubMed ID: 12027896
[TBL] [Abstract][Full Text] [Related]
3. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis.
Yang SP; Song ST; Tang ZM; Song HF
Acta Pharmacol Sin; 2003 Sep; 24(9):897-902. PubMed ID: 12956938
[TBL] [Abstract][Full Text] [Related]
4. Antisense ferritin oligonucleotides inhibit growth and induce apoptosis in human breast carcinoma cells.
Yang DC; Jiang X; Elliott RL; Head JF
Anticancer Res; 2002; 22(3):1513-24. PubMed ID: 12168831
[TBL] [Abstract][Full Text] [Related]
5. Influence of mRNA self-structure on hybridization: computational tools for antisense sequence selection.
Toschi N
Methods; 2000 Nov; 22(3):261-9. PubMed ID: 11071822
[TBL] [Abstract][Full Text] [Related]
6. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
8. Identification of potentially effective antisense oligodeoxyribonucleotide (ODN) sequences for inhibiting plasminogen activator inhibitor-2 (PAI-2) production by monocytes.
Humphries J; Burnand KG; Cunningham P; Brock A; Westwood N; Smith A
Thromb Haemost; 2002 Jul; 88(1):131-6. PubMed ID: 12152653
[TBL] [Abstract][Full Text] [Related]
9. ["Target secondary structural motif" in the action of antisense oligodeoxynucleotides].
Song HF; Tang ZM
Yao Xue Xue Bao; 2001 Aug; 36(8):585-9. PubMed ID: 12579934
[TBL] [Abstract][Full Text] [Related]
10. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries.
Ho SP; Bao Y; Lesher T; Malhotra R; Ma LY; Fluharty SJ; Sakai RR
Nat Biotechnol; 1998 Jan; 16(1):59-63. PubMed ID: 9447595
[TBL] [Abstract][Full Text] [Related]
11. Correlation between gene silencing activity and structural features of antisense oligodeoxynucleotides and target RNA.
Liao L; Li Z
In Silico Biol; 2007; 7(4-5):527-34. PubMed ID: 18391241
[TBL] [Abstract][Full Text] [Related]
12. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
[TBL] [Abstract][Full Text] [Related]
13. Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines.
Jekerle V; Kassack MU; Reilly RM; Wiese M; Piquette-Miller M
J Pharm Pharm Sci; 2005 Sep; 8(3):516-27. PubMed ID: 16401397
[TBL] [Abstract][Full Text] [Related]
14. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis.
Song HF; Tang ZM; Yuan SJ; Zhu BZ
Acta Pharmacol Sin; 2000 Jan; 21(1):80-6. PubMed ID: 11263253
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antiviral activity of antisense oligonucleotides against influenza virus].
Chen Z; Wang S; Guan W; Yang B; Sun Z
Wei Sheng Wu Xue Bao; 2000 Oct; 40(5):482-7. PubMed ID: 12548758
[TBL] [Abstract][Full Text] [Related]
16. Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA.
Walton SP; Stephanopoulos GN; Yarmush ML; Roth CM
Biophys J; 2002 Jan; 82(1 Pt 1):366-77. PubMed ID: 11751323
[TBL] [Abstract][Full Text] [Related]
17. Antisense activity detection by inhibition of fluorescence resonance energy transfer.
BenÃtez-Hess ML; DiPaolo JA; Alvarez-Salas LM
Luminescence; 2004; 19(2):85-93. PubMed ID: 15098208
[TBL] [Abstract][Full Text] [Related]
18. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides.
Hasselblatt P; Hockenjos B; Thoma C; Blum HE; Offensperger WB
Nucleic Acids Res; 2005; 33(1):114-25. PubMed ID: 15640448
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of bacterial RNase P RNA as a drug target.
Willkomm DK; Gruegelsiepe H; Goudinakis O; Kretschmer-Kazemi Far R; Bald R; Erdmann VA; Hartmann RK
Chembiochem; 2003 Oct; 4(10):1041-8. PubMed ID: 14523922
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of in vitro translation of esterase mRNA of dipterex-resistant mosquito (Culex pipiens pallens) by antisense nucleic acids].
Zhu HM; Zou YD
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2001; 19(6):333-5. PubMed ID: 12572062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
